Understanding patterns of pathologic response following neoadjuvant immunotherapy for solid tumors

L M Sholl¹

Affiliations

Free article

Editorial

L M Sholl. Ann Oncol. 2018.

Free article

. 2018 Aug 1;29(8):1630-1632.

doi: 10.1093/annonc/mdy227.

L M Sholl¹

¹ Department of Pathology, Brigham and Women's Hospital, Boston, USA. Electronic address: lmsholl@bwh.harvard.edu.

No abstract available

Comment on

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM. Cottrell TR, et al. Ann Oncol. 2018 Aug 1;29(8):1853-1860. doi: 10.1093/annonc/mdy218. Ann Oncol. 2018. PMID: 29982279 Free PMC article. Clinical Trial.